Fennec Pharmaceuticals Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited U.S. GAAP financial statements. Fennec is a commercial-stage biopharmaceutical company whose principal product is PEDMARK, approved in the U.S. to reduce cisplatin-associated hearing-loss risk in certain pediatric patients.
Financial performance and liquidity
Unless stated otherwise, amounts are U.S. dollars in millions. The income and cash-flow comparisons are against Q1 2023; balance-sheet comparisons are against December 31, 2023.
| Metric | Q1 2024 / March 31, 2024 | Comparable period / prior date |
|---|---|---|
| Net product sales | $7.419 | $1.677 in Q1 2023 |
| License revenue | $17.958 | None in Q1 2023 |
| Total revenue | $25.377 | $1.677 in Q1 2023 |
| Operating expenses | $11.634 | $6.947 in Q1 2023 |
| Operating income/(loss) | $13.743 | $(5.270) in Q1 2023 |
| Net income/(loss) | $12.837 | $(6.052) in Q1 2023 |
| Operating cash flow | $39.047 | $(5.577) in Q1 2023 |
| Cash and cash equivalents | $51.184 | $13.269 at December 31, 2023 |
| Working capital | $58.335 | $19.305 at December 31, 2023 |
| Term debt | $30.000 principal, plus $1.617 accrued PIK interest | $30.000 principal and $1.219 PIK interest at December 31, 2023 |
| Stockholders’ equity/(deficit) | $3.014 | $(11.622) at December 31, 2023 |
Cost of product sales was $0.550 million, including production, distribution costs and a 1% royalty on net sales. The filing does not present a standalone product gross-margin measure. Interest expense was $1.034 million, compared with $0.798 million a year earlier. Basic EPS is reported as $0.47 and diluted EPS as $0.41 in the statements of operations.
Q1 operating cash flow included a $25.246 million increase in the Norgine contract liability (deferred revenue); therefore, reported cash generation was materially supported by the licensing transaction and should not be read as recurring operating cash flow. Cash increased by $37.915 million overall, after $1.132 million of net financing cash outflow.
Material changes and business developments
- PEDMARK net sales increased by $5.742 million year over year. Gross product revenue was $9.556 million, reduced by $2.137 million of discounts and allowances.
- Under the March 2024 Norgine license and supply agreement, Fennec received approximately $43.2 million upfront. It recognized $17.958 million as license revenue in Q1 and recorded $25.246 million as a contract liability associated with future supply. The agreement covers commercialization of PEDMARQSI in the European Economic Area, Switzerland, the U.K., Australia and New Zealand.
- Norgine may also owe up to approximately $230 million in regulatory and commercial milestones, plus tiered royalties ranging from the mid-teens to the mid-twenties. These amounts are contingent; no Norgine milestone or royalty revenue was recognized in Q1.
- Selling and marketing expense rose to $5.209 million from $2.531 million, largely due to payroll and marketing. General and administrative expense increased to $5.872 million from $4.317 million, including higher consulting and professional costs associated largely with European pre-commercialization.
- Cash and working capital strengthened substantially following the Norgine upfront payment. Total liabilities were $66.179 million at March 31, 2024.
Outlook, risks and unusual items
- Management says existing funds and expected product-sales cash flows should support planned activities for at least the next 12 months. It expects the Norgine transaction to reduce the need for alternative financing. This is management’s outlook, not a guarantee; no specific revenue or earnings guidance is provided.
- The $30 million secured convertible notes mature August 19, 2027. Cash interest is prime plus 4.5% (11% as of March 31, 2024); PIK interest accrues at 3.5% and is scheduled to stop accruing August 24, 2024. Up to $15 million of additional financing may be drawn through December 31, 2024, subject to mutual agreement with the investor. The notes are secured by the company’s assets.
- The Norgine agreement’s future milestone and royalty receipts depend on sales and other events; royalties may be materially reduced if generic or alternative products become available in a territory. Revenue allocation and recognition involve estimates and judgment.
- CIPLA’s patent challenge and related U.S. infringement litigation remain ongoing. The PTAB invalidated the only claim of one licensed patent; Fennec reports other patents and applications covering PEDMARK. Adverse patent outcomes could weaken product protection. PEDMARK also has U.S. orphan-drug exclusivity through September 20, 2029, according to the filing.
- Management reported a material weakness in internal control over financial reporting relating to measurement and classification of distributor fees for distinct services and the timing of related expenses. Remediation has begun but is not complete; the weakness remains until remediation is implemented and tested.
- Approximately $49.870 million of cash was held in money-market investments, substantially above the $250,000 FDIC-insured amount. The company notes these balances may lose value. It also reports an allowance for credit losses of $1.103 million on trade receivables.
- Other notable obligations include OHSU royalties and potential milestones, operating leases, and executive severance commitments. The filing reports $0.077 million of OHSU royalty expense for Q1 and $0.314 million accrued as of March 31, 2024.
Important facts for investors to verify
- Confirm the sustainability of U.S. PEDMARK sales and the extent to which future cash flow depends on product sales rather than one-time license proceeds or deferred supply consideration.
- Track Norgine’s launch, supply-related contract-liability recognition, and progress toward contingent milestones and royalties.
- Review the secured debt’s interest burden, conversion terms, maturity, and the conditions for any additional borrowing.
- Monitor CIPLA litigation, patent validity and listing, and the remaining period of regulatory and patent protection.
- Follow remediation and independent testing of the disclosed material weakness in financial controls.
- Resolve filing presentation inconsistencies: the statements of operations show basic EPS of $0.47 and diluted EPS of $0.41, while the EPS note appears to report $0.41 for both; the balance-sheet comparative heading also appears inconsistent with the December 31, 2023 comparison used elsewhere.